Losartan Potassium Tablet, Film Coated
Product Images NDC 72789-179

6 FDA label images from Pd-rx Pharmaceuticals, Inc. · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 72789-179). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pd-rx Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image001 (Bf3fbbc7 Ee52 466f B5aa 3c6f8cebed32 01)

Image001 (Bf3fbbc7 Ee52 466f B5aa 3c6f8cebed32 01)
Chemical structure diagram of Losartan Potassium, an active ingredient in LOSARTAN POTASSIUM 50 mg oral tablets. The structure includes characteristic ring systems and potassium ion represented with molecular bonds and atomic symbols.*
FDA Label Image

Image002 (Bf3fbbc7 Ee52 466f B5aa 3c6f8cebed32 02)

Image002 (Bf3fbbc7 Ee52 466f B5aa 3c6f8cebed32 02)
A line graph comparing the percentage of patients with a primary endpoint over study months between Atenolol and Losartan potassium. The x-axis shows study months from 0 to 66, and the y-axis shows percentage from 0 to 16%. The graph includes an adjusted risk reduction statistic of 13% with a p-value of 0.021.*
FDA Label Image

Image003 (Bf3fbbc7 Ee52 466f B5aa 3c6f8cebed32 03)

Image003 (Bf3fbbc7 Ee52 466f B5aa 3c6f8cebed32 03)
A line graph comparing the percentage of patients with fatal or non-fatal stroke over study months between Atenolol and Losartan potassium. The vertical axis shows percentage of patients, and the horizontal axis indicates study duration in months up to 66. The graph shows Atenolol with higher incidence than Losartan potassium, which has a lower risk curve. An annotation states an adjusted risk reduction of 25% with Losartan potassium, p=0.001.*
FDA Label Image

Image004 (Bf3fbbc7 Ee52 466f B5aa 3c6f8cebed32 04)

Image004 (Bf3fbbc7 Ee52 466f B5aa 3c6f8cebed32 04)
A clinical study chart comparing the event rates and hazard ratios for Losartan Potassium versus Atenolol. The chart displays two panels: Primary Composite and Stroke (Fatal/Non-fatal), with event rates and hazard ratios listed by subgroup categories such as age, gender, race, ISH, diabetes, and history of cardiovascular disease. Hazard ratios are plotted with confidence intervals, showing which drug the data favors across different patient groups.*
FDA Label Image

Image005 (Bf3fbbc7 Ee52 466f B5aa 3c6f8cebed32 05)

Image005 (Bf3fbbc7 Ee52 466f B5aa 3c6f8cebed32 05)
A line graph depicting the percentage of patients with an event over 48 months comparing Losartan potassium and placebo. The y-axis shows % patients with event, while the x-axis represents time in months. The graph includes a note on risk reduction of 16.1% with Losartan potassium versus placebo with a p-value of 0.022.*
FDA Label Image

72789179 Label (72789179)

72789179 Label (72789179)
Packaging label for LOSARTAN POTASSIUM USP 50 MG film-coated tablets, containing 90 tablets per bottle. The label shows product name, strength, quantity, and identification details including NDC 72789-179-90. It is labeled by PD-Rx Pharmaceuticals, Inc., Oklahoma City, OK. The label includes lot number C21E11 and expiration date 09/2022. Dosage instructions blanks are present, with bilingual text in English and Spanish.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.